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Objectives: Upon disease progression or early termination of a trial, cancer 
patients in the control arm of clinical studies commonly switch to the experimental 
drug or receive other post-study treatments. The objective of this study was to assess 
the willingness of HTA agencies to accept the statistical methods that are available 
to adjust overall survival (OS) estimates for resulting bias. MethOds: PubMed and 
the ADIS R&D Insights database were searched to identify pivotal trials involv-
ing treatment switching. Related HTA appraisals, published between January 2011 
and February 2014, were then selected from the HTA agencies websites for further 
analysis. Reports from 10 agencies were considered for review. Results: Sixteen 
pivotal trials and 45 related HTA appraisals were selected for in-depth analysis. 
It was widely acknowledged by all HTA agencies that treatment switching could 
confound the OS estimates when an inferior drug is used as a comparator. Our 
analysis suggests that statistical adjustment methods are discussed more often 
and more thoroughly by agencies that base their decisions on cost-effectiveness 
outcomes. On one end, NICE accepts and reviews the selection and implementation 
of such methods in detail, and has recently developed its own guidelines on the 
appropriate handling of treatment switching. Various examples have been identi-
fied and accepted in SMC and PBAC submissions. TLV, ZiNL, pCODR and INESSS 
have accepted statistical adjustments in at least one case. No evidence of such 
adjustments was identified in the selected HAS reports. On the other end, recent 
case examples among IQWiG submissions suggest that they do not accept the use 
of these methods. cOnclusiOns: The rationale to adjust for treatment switching 
and the methods used need to be justified towards agencies accepting the correc-
tion techniques. Other payers will rather want to base their decision on results of 
the last “unbiased” dataset.
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Objectives: To empirically test whether and how framing of a risk attribute 
in a Discrete Choice Experiment (DCE) affects study results with respect to the 
relative importance of the attributes, trading behavior and potential uptake 
rates. MethOds: By means of ongoing data collection, two versions of a DCE- 
questionnaire containing nine D-efficiently designed choice tasks were distrib-
uted among a representative sample of the Dutch population aged 55-65years. The 
DCE consisted of four attributes related to the decision whether to participate in 
genetic screening for colorectal cancer (CRC). Three fixed attributes were; risk of 
being genetically predisposed, risk of developing CRC, and frequency of follow-up 
colonoscopies. The included risk attribute was framed positively as survival rate 
and negatively as mortality rate. Mixed logit models were conducted to estimate the 
relative importance of the attributes. Dominant decision behavior was determined 
and potential uptake rates were calculated. Results: Overall, risk attribute fram-
ing significantly interacted with most of the attribute level estimates. Based on 
the positive frame, the frequency of follow-up colonoscopies was most important 
followed by survival rate, while based on the negative fame, mortality rate was 
most important. Twice as many respondents dominated on the survival attribute 
compared to the mortality attribute. Potential uptake rates were calculated for mul-
tiple hypothetical scenarios, in all cases they were lower based on the data of the 
negative frame. cOnclusiOns: The use of a positive frame leads to significantly 
increased frequency of dominant choices. Negative framing of the risk attribute 
resulted in a different relative importance of the attributes and a lower willingness 
to participate in genetic screening for CRC compared to positive framing. These 
results call for greater attention and more research with regard to the impact of 
framing of risk attributes in DCEs aiming to elicit preferences within the health 
care or public health context.
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Objectives: Where data collected using a preferred utility instrument are not avail-
able, mappings may be available to link either disease specific or generic quality 
of life instruments to the preferred measure. The objective of this study was to 
investigate the similarity of a widely used older mapping from SF-36 to EQ-5D and 
a more recently published mapping linking the same two instruments. MethOds: 
Patient level SF-36 data from the PSUMMIT trials of ustekinumab versus placebo in 
psoriatic arthritis (PsA) were used to generate EQ-5D utilities based upon the older 
algorithm (Gray) and the newer algorithm (Rowen). A regression linking disease 
specific instruments to the resulting EQ-5D utilities, used in a published economic 
evaluation of anti-TNFα treatments for PsA, was also replicated to investigate the 
difference the choice of mapping would make if the results were used in economic 
analysis. Results: The mapping algorithms showed similar mean values (Gray 
= 0.572, Rowen = 0.568) and a large degree of agreement in estimates (R2 = 0.95). 
Objectives: New health technologies are required to demonstrate clinical- and 
cost-effectiveness before being recommended by NICE for use in the National 
Health Service. A large proportion of submissions are rejected, at least in part, 
due to poor trial design or flaws in the presented clinical data. Published NICE 
guidance includes a comprehensive critique of submitted clinical evidence. 
Therefore, the flaws in clinical data leading to rejection by NICE were examined, 
as a means of providing guidance for future submissions. MethOds: All single 
technology appraisals from January 2006 to May 2014 from NICE were included 
in the analysis. Multiple technology appraisals, resubmissions, vaccination pro-
grammes, and requests for advice were excluded. The recommendation and rea-
soning behind each decision were assessed, focusing on the critique of the clinical 
evidence. Results: 121 NICE submissions met the inclusion criteria, of which 28 
(19.8%) were rejected. Notable flaws in the presented clinical data were reported 
in 22 (78.6%) of the submissions. Major drivers of rejection due to clinical flaws 
included: uncertainty in the clinical evidence (32.1%), statistical flaws in trial 
design (28.6%), flaws in the choice of comparator (17.9%), and a perceived lack 
of transparency in trial design (14.3%). These factors contributed to a perceived 
failure to demonstrate clinical superiority over the comparator in 42.9% of the 
rejected submissions. cOnclusiOns: A failure to convincingly demonstrate clini-
cal superiority is a major driver in the rejection of submissions to NICE, often 
due to clinical trial design weaknesses or uncertainty surrounding the data pre-
sented. Manufacturers should not underestimate the need for effective planning 
and review of trial design early in the clinical development process, in order to 
avoid rejection by HTA agencies in later development stages.
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Objectives: Value-based assessment will be introduced into National Institute for 
Health and Care Excellence (NICE) appraisals where the willingness-to-pay above 
£20,000 will depend upon the wider societal impact (absolute shortfall of quality-
adjusted life years [QALYs]) and burden of illness (proportional QALY shortfall). The 
objective of this research was to re-evaluate past appraisals and determine whether 
there was a relationship between the absolute and proportional QALY shortfalls and 
the NICE decision. MethOds: Final incremental cost-effectiveness ratios (ICERs) 
were identified from NICE single technology appraisals published between January 
2013 and May 2014. The age that treatment commenced was taken from manu-
facturer submissions and combined with the average life expectancy in the UK to 
calculate the discounted QALYs accrued by a healthy person (X). Discounted QALYs 
accrued by current treatment were extracted from manufacturer submissions (Y). 
Consequently, absolute (X-Y) and proportional (absolute/X) QALY shortfalls were 
calculated for each condition. Logistic regression (LR) was performed on the data. 
Appraisals were excluded if the manufacturer submission was missing. Results: 
Of the appraisals assessed, 23 appraisals met the selection criteria; 13 were recom-
mended and 10 not recommended by NICE. The LR confirmed that the probability 
of an intervention being recommended was reduced significantly if the ICER was 
> £30,000 (p< 0.05). Taking into account the ICER, LR analysis demonstrated that 
neither the proportional nor absolute QALY shortfall had a significant effect on 
recommendation by NICE (p> 0.05). cOnclusiOns: These results suggest that in 
recent appraisals, proportional and absolute QALY shortfalls have had no significant 
effect on the NICE committee’s decisions, and that the introduction of value-based 
assessment may therefore cause a substantial change in the future outcomes of HTA 
processes. It is recognised that further appraisals before 2013 should be evaluated 
to confirm these results, as the sample size was small.
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bAckgROund: The UK’s National Institute for Health and Care Excellence (NICE) 
recently proposed amendments to its health technology appraisal methods. Previous 
amendments in 2009 and 2011 placed a greater value on the health of patients at the 
“end of life” and in cases where “treatment effects are both substantial in restoring 
health and sustained over a very long period”. The recent proposals repeal “end of 
life” considerations but add consideration of the “proportional” and “absolute” QALY 
loss from illness. NICE’s cost-effectiveness threshold may increase from £20,000 to 
£50,000 per QALY based upon these and four other considerations: “certainty of 
the ICER”; if health related quality of life is “inadequately captured”; the “innova-
tive nature” of the technology; and “non-health objectives of the NHS”. AnAlysis: 
We demonstrate that NICE’s previous amendments are flawed for two reasons: 
they contain logical inconsistencies which can result in different values being 
placed on health gains for identical patients, and they do not apply value weights 
to patients bearing the opportunity cost of NICE’s recommendations. The newly 
proposed amendments also suffer from a third flaw that the suggested weightings 
are poorly justified. The second of the three flaws is particularly significant, as the 
failure to apply special considerations to displaced services may result in NICE’s 
cost-effectiveness threshold being too high to adequately represent opportunity 
cost. Furthermore, the baseline threshold of £20,000 per QALY is greater than current 
estimates of the opportunity cost. Overall, these flaws likely lead to several undesir-
able consequences including age discrimination, a systematic bias in favour of new 
interventions over existing services, and the displacement of effective interventions 
by less effective interventions. cOnclusiOn: NICE’s proposed threshold range is 
too high, for empirical and methodological reasons. NICE’s proposals will harm 
the health of unidentified patients, whilst privileging the identified beneficiaries 
of new health technologies.
